2- (4- methoxyphenyl)ethyl- 2- acetamido- 2- deoxyglucopyranoside

has neuroprotective activity; structure in first source

Also Known As:

2-(4-methoxyphenyl) ethyl-2-acetamido-2-deoxyglucopyranoside; 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxy-beta-D-pyranoside; GlcNAc-Sal; SalA-4g

Networked: 7 relevant articles (2 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Amino Sugars: 110
  - Hexosamines: 733
    - Glucosamine: 1771
      - Acetylglucosamine: 922
        2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxyglucopyranoside: 7

Experts

1.	Ding, Fei: 6 articles (09/2021 - 01/2014)
2.	Yu, Shu: 5 articles (09/2021 - 06/2014)
3.	Xu, Hui: 4 articles (09/2021 - 01/2016)
4.	Yang, Yumin: 4 articles (09/2021 - 06/2014)
5.	Shen, Yuntian: 2 articles (09/2021 - 01/2016)
6.	Cheng, Qiong: 2 articles (11/2018 - 06/2014)
7.	Chi, Xiaojing: 2 articles (11/2018 - 01/2018)
8.	Wei, Li: 2 articles (11/2018 - 01/2018)
9.	Chen, Xia: 2 articles (01/2014 - 11/2013)
10.	Deng, Aiqing: 2 articles (01/2014 - 11/2013)

Related Diseases

1.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/01/2018 - "Fluorine-18-fluorodeoxyglucose PET/CT imaging indicated that SalA-4g improved metabolic recovery in the ischemic hemisphere in a rat middle cerebral artery occlusion model. " 01/01/2018 - "In this study, the pharmacological properties of SalA-4g were evaluated in primary cortical neurons exposed to oxygen and glucose deprivation and in a rat model of transient middle cerebral artery occlusion. " 06/15/2014 - "In this study, we showed that SalA-4g promoted neuronal survival and inhibited neuronal apoptosis in primary hippocampal neurons exposed to oxygen and glucose deprivation (OGD) and in rats subjected to ischemia by transient middle cerebral artery occlusion (MCAO), respectively, and that SalA-4g was more neuroprotective than salidroside. "
2.	Stroke (Strokes) 11/01/2018 - "SalA-4g dose-dependently improved stroke outcome. "
3.	Ischemia 11/01/2018 - "Either pre-treatment or post-treatment of SalA-4g exhibited notable neuroprotection, and maintained for up to 6 h after ischemia onset. " 09/28/2021 - "We have previously shown that SalA-4g elevates levels of protein O-GlcNAc and improves neuronal tolerance to ischemia. " 06/15/2014 - "In this study, we showed that SalA-4g promoted neuronal survival and inhibited neuronal apoptosis in primary hippocampal neurons exposed to oxygen and glucose deprivation (OGD) and in rats subjected to ischemia by transient middle cerebral artery occlusion (MCAO), respectively, and that SalA-4g was more neuroprotective than salidroside. "
4.	Brain Ischemia (Cerebral Ischemia) 11/01/2018 - "Here, we systematically investigated the therapeutic time window and dosage of SalA-4g in permanent focal cerebral ischemia in rats. " 01/01/2014 - "Our findings suggest that GlcNAc-Sal pretreatment prevents brain ischemia reperfusion injury by the direct or indirect suppression of cell apoptosis and GlcNAc-Sal could be developed as a broad-spectrum agent for the prevention and/or treatment of cerebral ischemic injury." 01/01/2014 - "The purpose of the current study was to investigate the neuroprotective effects of GlcNAc-Sal against oxygen-glucose deprivation-reperfusion (OGD-R)-induced neurotoxicity in vitro and global cerebral ischemia-reperfusion (GCI-R) injury in vivo. "
5.	Ischemic Stroke 11/01/2018 - "We suggest that data of this study are critical in exploring the clinical application prospects of SalA-4g for the treatment of ischemic stroke." 01/01/2016 - "The therapeutic benefits of combined treatment with tPA and SalA-4g for ischemic stroke might be associated with its effects on cerebral glucose metabolism."

Related Drugs and Biologics

1.	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)
2.	Glucose (Dextrose)
3.	Oxygen (Dioxygen)
4.	rhodioloside
5.	Neuroprotective Agents
6.	Caspase 3 (Caspase-3)
7.	Proteins (Proteins, Gene)